Barclays analyst Balaji Prasad lowered the firm’s price target on Pacira (PCRX) to $17 from $25 and keeps an Equal Weight rating on the shares. The company’s Q3 revenue missed consensus by 6%, with Exparel in-line and strong gross margin at 78%, the analyst tells investors in a research note.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX: